Side effects and watch-outs
- Nausea (very common on initiation)
- Vomiting
- Diarrhoea
- Decreased appetite
- Injection site reaction
- Tachycardia (glucagon component)
- ⚠️ Hypoglycaemia risk with concurrent diabetes medications
- Headache
- Constipation
Peptide / Metabolic
Mazdutide (IBI362)
GLP-1/glucagon dual receptor agonist. Chinese-developed once-weekly injectable. Phase 3 trials for obesity and T2DM. Shows strong weight loss, hepatic fat reduction, and glycaemic control. Similar mechanism to survodutide with comparable efficacy profile. Not yet approved outside clinical trials.
Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.